# The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

> **NCT02650102** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanxi Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Olanzapine
- **DRUG:** Quetiapine
- **DRUG:** Aripiprazole
- **DRUG:** Ziprasidone

## Key facts

- **NCT ID:** NCT02650102
- **Lead sponsor:** Shanxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2016-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02650102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02650102, "The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02650102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*